RGC
Regencell Bioscience Holdings Limited
Set alert
6.71 USD -0.15 -2.19%
6.53 Day range 7.05
4.78 52-week range 52.88
- YTD
- -68.05%
- 1 year
- -58.96%
- Open
- 6.89
- Prev close
- 6.86
- Mkt cap
- 3.33B
- Vol
- 148.17K
- Avg vol
- 249.90K
- EPS
- -0.02
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.53
- High
- 7.05
- Forward P/E
- 0.00
- Beta
- 1.17
- Short ratio
- 1.71
- Inst. own
- 0.28%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 6.80
- 200-d avg
- 17.29
- 1y target
- 0.00
Key statistics
- Market cap
- 3.34B
- Enterprise value
- 3.39B
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 249.26
- EPS (TTM)
- -0.02
- Beta
- 1.17
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -2.99M
- Total cash
- 14.19M
- Total debt
- 295.81K
- Return on equity
- -128.53%
- Shares outstanding
- 495.88M
- Short % of float
- 0.79%
- 50-day average
- 6.80
- 200-day average
- 17.29
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
RGC Revenue — annual 0
RGC Net income — annual -11.70M
RGC EPS — annual -0.024
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 28, 2026 | Jun 30, 2026 | — | -0.0129 | — | — |
| Jun 15, 2026 | Dec 31, 2025 | — | -0.0107 | — | — |
| Nov 18, 2025 | Jun 30, 2025 | — | -0.0035 | — | — |
| Jun 26, 2025 | Dec 29, 2024 | — | -0.14244 | — | — |
| Oct 25, 2024 | Jun 30, 2024 | — | -0.0045 | — | — |
| Jan 26, 2024 | Dec 30, 2023 | — | 0.00 | — | — |
About Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Limited focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, TCM brain theory, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Hong Kong
- Website
- regencellbioscience.com
News
Your note
Sign in to keep a note on RGC — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.09% | 422,011 | 2.84M | Jun 29, 2026 |
| Alyeska Investment Group, L.p. | 0.08% | 416,261 | 2.80M | Jun 29, 2026 |
| Legal & General Group PLC | 0.03% | 128,000 | 861.44K | Jun 29, 2026 |
| Jane Street Group, LLC | 0.02% | 98,348 | 661.88K | Jun 29, 2026 |
| Quadrature Capital Ltd | 0.01% | 41,750 | 280.98K | Jun 29, 2026 |
| Amundi | 0.01% | 47,159 | 317.38K | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.06% | 301,859 | 2.03M | Aug 30, 2026 |
| Fidelity Commonwealth Trust-Fidelity Nasdaq Composite Index ETF | 0.02% | 121,511 | 817.77K | Sep 29, 2026 |
| John Hancock Variable Insurance Trust-Total Stock Market Index Trust | 0.00% | 7,602 | 51.16K | Jun 29, 2026 |
| Invesco Exch-Trd Fd. TRT II-Invesco S&P Emerging Markets Momentum ETF | 0.00% | 478 | 3.22K | Aug 30, 2026 |
| SPDR INDEX SHARES FUNDS-State Street SPDR S&P China ETF | 0.00% | 4,051 | 27.26K | Sep 29, 2026 |